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Proposal for curing multiple sclerosis by genetically engineering oligodendrocytes
Amanda Moses
Department of Biological and Environmental Sciences
Longwood University, Farmville, Virginia
What is Multiple Sclerosis?

Potential Pitfalls

• A chronic T cell mediated autoimmune
disease1
• Affects the central nervous system (CNS) by
causing irreversible damage to the myelin
sheath2,3 (Figure 1)
• Two stages4:
1. Relapsing-Remitting
2. Progressive

Figure 4. MRI of M.S A
healthy brain vs a brain that
has been damaged due to the
lesions that form as a result
of multiple sclerosis

Figure 1. Multiple Sclerosis. The driver for M.S is
the lesions that form in the myelin sheath causing
issues in communication between the brain and
the muscles

Possible Causes of Multiple Sclerosis
• CD4+ T cells are activated in the periphery5
(Figure 2)
• B Cells are the key effectors for onset of
the disease5
• Low serum levels of Vitamin D6
• Smoking6
• Childhood obesity6
• Repeated infections of the Epstein-Barr virus6
• Genetics6

• Using neural stem cells for remyelination is a novel concept
• Mice do not respond to any of the three key myelin producing
genes (Figure 4)
• If mice do not respond to the three key myelin producing
genes, change it to the seven myelin peptides

Potential Conclusions
• 1.The 3 key meylin producing genes together work as
hypothesized
• 2. Two of the 3 key genes together fix the myelin sheath
• 3. One of the 3 key myelin genes by itself causes remyelination
• For this to support the hypothesis:
- Remyelination occurs
- Disease progression is halted
- No new symptoms occur
- Old symptoms disappear
• If this occurs, then a possible new treatment and cure could
become available (Figure 5).

Figure 2. Causes for M.S. The
possible causes broken down by
category.

Why try to find a cure?
• Current treatments/therapies only slow the
progression of the disease
• ~ 2.5 million people worldwide are affected
- Between 400,000 and 570,000 in the U.S1
• Diagnoses usually occurs between the ages of 20
and 407
• Affects women more commonly than men7 (Figure
3)
• No two cases are the same
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• Find a cure for Multiple Sclerosis through genetically engineering neural stem cells, specifically the
oligodendrocytes.
• Oligodendrocytes will be treated with chemotherapy in order to forget their memory of Multiple
Sclerosis
• The three key myelin genes (PLP1, MBP, and MOG) will be introduced to cause remyelination when
introduced
• Hypothesis: Genetically engineering the neural stem cells will remyelinate the myelin sheath and
stop lesions from forming.
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Methods
Mouse model used
in study

Chemotherapy to forget
memory of M.S
MRI to determine
disease activity

GraphPad Prism 4 and one
way ANOVA for statistical
analysis

Response to
txt measured
3 key myelin
genes split into
txt groups

Txt response
tested by MRI and
amount of lesions

